In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Vascular Biogenics (VBLT – Research Report), with a price target of $3.75. The company’s shares closed last Monday at $1.45.
According to TipRanks.com, Roy is a 3-star analyst with an average return of 0.3% and a 24.7% success rate. Roy covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Monopar Therapeutics Inc, and Aeglea Biotherapeutics.
Currently, the analyst consensus on Vascular Biogenics is a Strong Buy with an average price target of $3.00, representing a 91.1% upside. In a report issued on March 19, Oppenheimer also maintained a Buy rating on the stock with a $2.00 price target.
Based on Vascular Biogenics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $126K and GAAP net loss of $5.73 million. In comparison, last year the company earned revenue of $141K and had a GAAP net loss of $3.87 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi’in, Israel.